Hinge Health president sells 33,000 shares

Hinge Health, Inc. President James Pursley sold 33,000 shares of Class A Common Stock in open-market transactions.

Rhea-AI Filing Summary

Hinge Health, Inc. President James Pursley sold 33,000 shares of Class A Common Stock in open-market transactions. The sales occurred on June 22, 2026 across three trades at weighted average prices of $68.93, $69.82 and $70.89 per share.

The transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, indicating they were scheduled in advance rather than timed discretionarily.

Insights

Equity analyst

Pre-planned 33,000-share sale by Hinge Health’s president looks routine.

Hinge Health President James Pursley sold 33,000 shares of Class A Common Stock on June 22, 2026, via three open-market transactions at weighted average prices between about $68.93 and $70.89 per share.

The filing states these sales were made under a Rule 10b5-1 trading plan adopted on June 13, 2025, meaning the trades were scheduled in advance. That typically signals routine portfolio management rather than a reaction to short-term news.

No derivative exercises or tax-related share withholdings appear in this filing, and there is no additional financial or strategic information beyond the insider’s planned stock sales.

Insider Trade Summary 10b5-1

Net Seller: 33,000 shares

Net Sell 3 txns

Insider Pursley James

Role President

Sold 33,000 shs ($2.29M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	21,935	$68.9271	$1.51M
Sale	Class A Common Stock	8,507	$69.8247	$594K
Sale	Class A Common Stock	2,558	$70.89	$181K

Holdings After Transaction: Class A Common Stock — 740,897 shares (Direct)

Footnotes (4)

1. F1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025.
2. F2. Represents the weighted average sale price. The lowest price at which shares were sold was $68.35 and the highest price at which shares were sold was $69.34. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. F3. Represents the weighted average sale price. The lowest price at which shares were sold was $69.35 and the highest price at which shares were sold was $70.345. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
4. F4. Represents the weighted average sale price. The lowest price at which shares were sold was $70.36 and the highest price at which shares were sold was $71.34. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Key Figures

Shares sold: 33,000 shares Sale price tranche 1: $68.9271 per share Sale price tranche 2: $69.8247 per share +5 more

8 metrics

Shares sold 33,000 shares Total open-market sales on June 22, 2026

Sale price tranche 1 $68.9271 per share Weighted average price for 21,935-share sale

Sale price tranche 2 $69.8247 per share Weighted average price for 8,507-share sale

Sale price tranche 3 $70.8900 per share Weighted average price for 2,558-share sale

Lowest sale price $68.35 per share Footnote F2 price range for June 22, 2026 sales

Highest sale price $71.34 per share Footnote F4 price range for June 22, 2026 sales

10b5-1 plan adoption date June 13, 2025 Date Pursley adopted Rule 10b5-1 trading plan

Sell transactions count 3 transactions Number of open-market sales reported

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Class A Common Stock, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price. The lowest price at which shares were sold..."

Class A Common Stock financial

"security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Hinge Health (HNGE) President James Pursley report in this Form 4?

James Pursley reported selling 33,000 Hinge Health shares. On June 22, 2026, he executed three open-market sales of Class A Common Stock at weighted average prices between about $68.93 and $70.89 per share, according to the Form 4 filing.

At what prices did Hinge Health (HNGE) shares sell in James Pursley’s June 22, 2026 trades?

The reported weighted average sale prices ranged from about $68.93 to $70.89. Footnotes show trade price ranges between $68.35 and $71.34 per share, reflecting multiple individual executions within each reported transaction.

How many Hinge Health (HNGE) shares did James Pursley sell in total?

James Pursley sold a total of 33,000 shares. The Form 4 transaction summary aggregates three open-market sales of 2,558 shares, 8,507 shares and 21,935 shares of Class A Common Stock, all dated June 22, 2026.

Were James Pursley’s Hinge Health (HNGE) stock sales pre-planned under a Rule 10b5-1 plan?

Yes, the sales were made under a Rule 10b5-1 trading plan. A footnote states they were effected pursuant to a trading plan adopted on June 13, 2025, indicating the transactions were scheduled in advance rather than decided at the time of sale.

Did the Hinge Health (HNGE) Form 4 show any option exercises or derivative transactions?

No, the Form 4 only reports open-market sales of common stock. The derivative transaction count is zero in the transaction summary, and there are no option exercises, conversions, gifts, or tax-withholding entries disclosed in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:52 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pursley James

(Last) (First) (Middle)

C/O HINGE HEALTH, INC.

455 MARKET STREET, SUITE 700

(Street)

SAN FRANCISCO CALIFORNIA 94105

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/22/2026		S(1)		21,935	D	$68.9271(2)	751,962	D
Class A Common Stock	06/22/2026		S(1)		8,507	D	$69.8247(3)	743,455	D
Class A Common Stock	06/22/2026		S(1)		2,558	D	$70.89(4)	740,897	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $68.35 and the highest price at which shares were sold was $69.34. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Represents the weighted average sale price. The lowest price at which shares were sold was $69.35 and the highest price at which shares were sold was $70.345. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

4. Represents the weighted average sale price. The lowest price at which shares were sold was $70.36 and the highest price at which shares were sold was $71.34. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

	/s/ James Budge, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)